Consensus statement for the diagnosis and treatment of drug-induced lung injuries

Respiratory Investigation

Volumn 51, Issue 4, 2013, Pages 260-277

  Kubo, Keishi ^a   Azuma, Arata ^b   Kanazawa, Minoru ^c   Kameda, Hideto ^d   Kusumoto, Masahiko ^e   Genma, Akihiko ^b   Saijo, Yasuo ^f   Sakai, Fumikazu ^g   Sugiyama, Yukihiko ^h   Tatsumi, Koichiro ⁱ   Dohi, Makoto ^j   Tokuda, Hitoshi ^k   Hashimoto, Shu ^l   Hattori, Noboru ^m   Hanaoka, Masayuki ^a   Fukuda, Yuh ^b  

^a Nagano Prefectural Hospital Organization   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^g SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^h JICHI MEDICAL UNIVERSITY   (Japan)

ⁱ CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k Social Insurance Central General Hospital   (Japan)

^l NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m HIROSHIMA UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; BLEOMYCIN; BORTEZOMIB; CETUXIMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; HERBACEOUS AGENT; HYDRALAZINE; INTERFERON; LEFLUNOMIDE; METHOTREXATE; PANITUMUMAB; PENICILLAMINE; PSYCHOTROPIC AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; TEMSIROLIMUS; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG;

ACUTE LUNG INJURY; ALLERGIC PNEUMONITIS; ALLERGIC REACTION; ANAPHYLAXIS; ASTHMA; BLOOD ANALYSIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; BRONCHOCONSTRICTION; BRONCHOSPASM; CONSENSUS DEVELOPMENT; DIFFERENTIAL DIAGNOSIS; DIFFUSE ALVEOLAR DAMAGE; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG INDUCED LUNG INJURY; DRUG RESPONSE; DRUG WITHDRAWAL; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LOEFFLER PNEUMONIA; LOW DRUG DOSE; LUNG EDEMA; LUNG EMBOLISM; LUNG FIBROSIS; LUNG HEMORRHAGE; LUNG INJURY; LUNG LAVAGE; MEDICAL HISTORY; NONCARDIOGENIC LUNG EDEMA; ORGANIZING PNEUMONIA; PATHOGENESIS; PHYSICAL EXAMINATION; PLEURA EFFUSION; PNEUMONIA; PULMONARY HYPERTENSION; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYMPTOM; TRANSBRONCHIAL BIOPSY;

ACUTE LUNG INJURY; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; BRONCHIAL PROVOCATION TESTS; DIAGNOSTIC IMAGING; DRUGS, CHINESE HERBAL; HEMATOLOGIC TESTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERONS; JAPAN; LUNG DISEASES, INTERSTITIAL; LYMPHOCYTE ACTIVATION; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84887621217     PISSN: 22125345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resinv.2013.09.001     Document Type: Review

References (52)

1. ICH harmonised tripartite guideline; clinical safety data management: definitions and standards for expedited reporting. [Internet]. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH); 1994 October 27. Available from:. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
2. Azuma A., Kudoh S. High prevalence of drug-induced pneumonia in Japan. Jpn Med Assoc J 2007, 50(5):405-411.
3. Pharmaceuticals and medical devices safety information [Internet]. Tokyo: Ministry of Health, Labour and Welfare. Available from: [Japanese]. http://www1.mhlw.go.jp/kinkyu/iyaku_j/iyaku_j/anzenseijyouhou.html.
4. Inoue A., Saijo Y., Maemondo M., et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003, 361(9352):137-139.
5. Pharmaceuticals and Medical Devices Information Website [Internet]. Tokyo: Pharmaceuticals and Medical Devices Agency, Japan. Available from: [Japanese]. http://www.info.pmda.go.jp/.
6. Kudoh S., Kato H., Nishiwaki Y., et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 2008, 177(12):1348-1357.
7. Azuma A., Hagiwara K., Kudoh S. Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients. Am J Respir Crit Care Med 2008, 177(12):1397-1398.
8. Fiorentino D., Chung L., Zwerner J., et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011, 65(1):25-34.
9. Kameda H., Takeuchi T. Recent advances in the treatment of interstitial lung disease in patients with polymyositis/dermatomyositis. Endocr Metab Immune Disord Drug Targets 2006, 6(4):409-415.
10. AstraZeneca KK. The final report of the specialist committee on acute lung injury/interstitial pneumonia induced by gefitinib (Iressa® tablets 250); 2003 [Japanese].
11. Mukai H, et al. 72nd Annual Meeting of the Japanese Society of Hematology; 2010.
12. U.S. Food and Drug Administration. Prescribing information for Tarceva; 2009.
13. Camus P., Fanton A., Bonniaud P., et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004, 71(4):301-326.
14. Kohno N., Awaya Y., Oyama T., et al. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease. Am Rev Respir Dis 1993, 148(3):637-642.
15. Ohnishi H., Yokoyama A., Yasuhara Y., et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003, 58(10):872-875.
16. Kondo A. Drug-induced pneumonitis. Kekkaku 1999, 74(1):33-41. [Japanese].
17. Cleverley J.R., Screaton N.J., Hiorns M.P., et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002, 57(4):292-299.
18. Oonakahara K., Higashimoto I., Arimura K., et al. Clinical characteristics of drug-induced lung diseases, including bronchiolitis obliterans associated with consumption of Sauropus androgynus. Kokyu 2004, 23:540-545. ([Japanese]).
19. Costabel U., Uzaslan E., Guzman J. Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004, 25(1):25-35.
20. Lee-Chiong T., Matthay R.A. Drug-induced pulmonary edema and acute respiratory distress syndrome. Clin Chest Med 2004, 25(1):95-104.
21. Bernard G.R., Artigas A., Brigham K.L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994, 149(3 Pt 1):818-824.
22. Chihara R., Nakamoto H., Arima H., et al. Systemic capillary leak syndrome. Intern Med 2002, 41(11):953-956.
23. Tatsukawa Y., Mikuriya Y. Drug-induced respiratory dysfunction: pulmonary edema. Iyaku J 1995, 31:2225-2229. [Japanese].
24. Briasoulis E., Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 2001, 6(2):153-161.
25. Ishikawa H., Ohtsuka M., Sekizawa K. 4. Drug-induced vascular lesions; 4. Drug-induced pulmonary edema. Drug-Induced Respiratory Dysfunction 2005, 44-50. Kokuseido Co., Ltd., Tokyo, [Japanese]. Y. Yoshizawa (Ed.).
26. Allen J.N., Pacht E.R., Gadek J.E., et al. Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure. N Engl J Med 1989, 321(9):569-574.
27. Allen J.N. Drug-induced eosinophilic lung disease. Clin Chest Med 2004, 25(1):77-88.
28. Camus P., Fanton A., Bonniaud P., et al. Interstitial lung disease induced by drugs and radiation. Respiration 2004, 71(4):301-326.
29. Solomon J., Schwarz M. Drug-, toxin-, and radiation therapy-induced eosinophilic pneumonia. Semin Respir Crit Care Med 2006, 27(2):192-197.
30. Simonneau G., Robbins I.M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009, 54(1 Suppl.):S43-S54.
31. Katz U., Zandman-Goddard G. Drug-induced lupus: an update. Autoimmun Rev 2010, 10(1):46-50.
32. Pneumotox® Website: Last update 2012-v2. http://www.pneumotox.com.
33. Limper A.H. Chemotherapy-induced lung disease. Clin Chest Med 2004, 25(1):53-64.
34. Pharmaceuticals and medical devices safety information no. 206 [Internet]. Tokyo: Ministry of Health, Labour and Welfare; 2004. Available from: [Japanese]. http://www.mhlw.go.jp/houdou/2004/10/h1028-2a.html.
35. Chugai Pharmaceutical Co., Ltd. Tarceva® specified drug-use survey (all-case surveillance): final analysis report on 3000 cases. 2010 [Japanese].
36. Okusaka T., Furuse J., Funakoshi A., et al. Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 2011, 102(2):425-431.
37. White D.A., Camus P., Endo M., et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010, 182(3):396-403.
38. Pfizer Japan Inc. TORISEL® injection 25mg appropriate use guidelines [Japanese].
39. Maroto J.P., Hudes G., Dutcher J.P., et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011, 29(13):1750-1756.
40. Tokuda H., Sakai F., Yamada H., et al. Clinical and radiographical features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. Intern Med 2008, 47(10):915-923.
41. Alarcón G.S., Kremer J.M., Macaluso M., et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997, 127(5):356-364.
42. Searles G., McKendry R.J. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987, 14(6):1164-1171.
43. Ohosone Y., Okano Y., Kameda H., et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol 1997, 24(12):2299-2303.
44. Shidara K., Hoshi D., Inoue E., et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 2010, 20(3):280-286.
45. Kameda H., Tokuda H., Sakai F., et al. Clinical and radiological features of acute-onset diffuse interstitial lung diseases in patients with rheumatoid arthritis receiving treatment with biological agents: importance of Pneumocystis pneumonia in Japan revealed by a multicenter study. Intern Med 2011, 50(4):305-313.
46. Koike R., Takeuchi T., Eguchi K., et al. Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol 2007, 17:451-458.
47. Sato A., Toyoshima M., Kondo A., et al. Pneumonitis induced by the herbal medicine Sho-saiko-to in Japan. Nihon Kyobu Shikkan Gakkai Zasshi 1997, 35(4):391-395. [Japanese].
48. Suzuki H., Kumada H., Sato A., et al. Guidelines of Sho-saiko-to/Xiao-Chaihu-Tang treatment in patients with chronic hepatitis C. Wakan Iyakugaku Zasshi 2000, 17(3):95-100. [Japanese].
49. Ueda T., Ohta K., Suzuki N., et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992, 146(1):266-268.
50. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995, 333(2):77-82.
51. Yamada Y., Shiga T., Matsuda N., et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J 2007, 71(10):1610-1616.
52. Papiris S.A., Triantafillidou C., Kolilekas L., et al. Amiodarone: review of pulmonary effects and toxicity. Drug Saf 2010, 33(7):539-558.